NCT04435522View on ClinicalTrials.gov

Maraviroc in Patients With Moderate and Severe COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
COVID
Interventions
DRUG

Maraviroc

Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).

Trial Locations (1)

02908

Rhode Island Hospital, Providence

All Listed Sponsors
lead

Rhode Island Hospital

OTHER

NCT04435522 - Maraviroc in Patients With Moderate and Severe COVID-19 | Biotech Hunter | Biotech Hunter